<DOC>
	<DOCNO>NCT02474927</DOCNO>
	<brief_summary>The clinical trial Phase II open label , single-arm pilot study evaluate safety efficacy combination therapy carfilzomib , plasma exchange intravenous immunoglobulin AMR lung transplantation elucidate important clinical immunologic phenotype mechanisms associate outcome .</brief_summary>
	<brief_title>Combination Therapy With Carfilzomib Antibody-Mediated Rejection Diagnosis Lung Transplantation</brief_title>
	<detailed_description>The main objective propose clinical investigation evaluate effect carfilzomib addition conventional therapy short-term outcome diagnosis antibody-mediated rejection lung transplant recipient . In study , Carfilzomib administer dose 20 mg/m2 two consecutive day , week three week ( Days 1 2 , 8 , 9 , 15 , 16 ) constitute one therapeutic cycle . Carfilzomib may administer 1-2 complete cycle study . Patients follow duration hospital admission enrollment . Post treatment follow-up also occur Days 42 90 .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Adult lung transplant recipient â‰¥ 18 year age meet diagnostic criterion AMR underwent PFT test unless intubate transbronchial biopsy prior enrollment . Direct contraindication previous intolerance component standard care regimen include PLEX , 5 % human albumin , 5 % gammagard S/D 10 % gammagard liquid Leukopenia Neutropenia Thrombocytopenia Known ChildPugh B/C cirrhosis Total bilirubin &gt; 4 ALT &gt; 90 Known systolic heart failure LVEF &lt; 40 % Known pulmonary hypertension Any uncontrolled comorbid condition Pregnant woman Breastfeeding woman Ongoing bacterial fungal viral infection lifethreatening Active cytomegalovirus disease Active varicella zoster infection Previous intolerance carfilzomib Concurrent use another proteasome inhibitor ( e.g. , bortezomib )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>antibody-mediated rejection</keyword>
	<keyword>lung transplant</keyword>
	<keyword>Carfilzomib</keyword>
</DOC>